It is well accepted that the biological agents such as anti‐TNFα‐neutralizing antibodies (etanercept, infliximab, and adalimumab, etc.)and anti‐IL‐6‐neutralizing antibody (tocilizumab) target NF‐κB pathway to prevent joint destruction of RA patients.201. Here, TNF is linked to rheumatoid arthritis.